Staar Surgical (NSDQ:STAA) said today it inked a strategic cooperation agreement with ophthalmology clinic group Vista Oftalmólogos to offer its Evo Visian implantable collamer lenses for patients suffering from nearsightedness.
Vista Oftalmólogos is a 49-clinic group across Spain, France, Portugal and Morocco and employs more than 200 eye doctors and has 1,000 employees, Monrovia, Calif.-based Staar Surgical said.
“Providing the highest level of science-backed vision services to ensure satisfied patients is the common endeavor of every Vista clinic and the Evo Visian ICL fulfills that goal fitting seamlessly into our clinics. Some of our surgeons have used the ICL for years while others are just beginning the journey in providing this life-changing vision correction solution to our patients. With the ICL we have the added plus of a manufacturing company that meets our surgeons’ expectations, which is no small feat in this business. This new strategic cooperation agreement with Staar elevates the importance of the ICL in providing our patients a safe quick vision correction procedure with unmatched levels of patient satisfaction,” Vista Oftalmólogos manager Juan Borreguero said in a press release.
Staar Surgical’s Evo ICL is intended to work with a patient’s natural eye to correct vision and eliminate the need for external corrective lenses. The company said that the Evo lens allows for natural aqueous flow and only requires a single surgical procedure.
“In 10 short years Vista Oftalmólogos has established itself as a leading ophthalmology group in Western Europe and we are delighted they have chosen to make our Evo Visian ICL family of lenses a premium and primary procedure in their clinics. Precision manufactured with our exclusive Collamer material the Evo lens has a well-recognized safety and effectiveness record for the more than 500,000 EVO lenses that have been implanted. The Staar team looks forward to working closely with Vista Oftalmólogos on certifying surgeons, patient education and marketing to facilitate broader awareness and use of the ICL,” Staar Surgical prez & CEO Caren Mason said in a prepared statement.
